Screener
BridgeBio Pharma BBIO Payment Of Deferred Royalty Obligation
Payment Of Deferred Royalty Obligation at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:PaymentOfDeferredRoyaltyObligation.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
FAQ
- What is BridgeBio Pharma's payment of deferred royalty obligation?
- BridgeBio Pharma (BBIO) reported payment of deferred royalty obligation of $21.79M in Q2 2026.
- How has BridgeBio Pharma's payment of deferred royalty obligation changed year-over-year?
- BridgeBio Pharma's payment of deferred royalty obligation increased by 1070.8% year-over-year, from $1.86M to $21.79M.
- What does payment of deferred royalty obligation mean?
- Payment Of Deferred Royalty Obligation as reported by BridgeBio Pharma, Inc. Common Stock.
Ask your AI about BridgeBio Pharma's payment of deferred royalty obligation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude